Vanguard Capital Management
GLSI icon

Vanguard Capital Management’s Greenwich LifeSciences GLSI Stock Holding History

Vanguard Capital Management’s Portfolio GLSI Stock Details GLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.53M Sell
278,190
-20,076
-7% -$488K ﹤0.01% 3020
2026
Q1 		$7.16M Buy
+298,266
New +$7.78M ﹤0.01% 2904

Other funds holding GLSI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Vanguard Capital Management's GLSI Position: Q2 2026 in Review

Vanguard Capital Management reduced its Greenwich LifeSciences (GLSI) stake by 6.7% in Q2 2026, selling an estimated $488K and leaving 278,190 shares worth $6.53M. The position accounts for ﹤0.01% of the portfolio, ranked #3020.

Vanguard Capital Management first reported a position in GLSI in Q1 2026 and has held it in 2 quarters since. The position peaked at $7.16M in Q1 2026. 58 funds tracked by Wall St. Rank hold GLSI as of Q2 2026.

  • Vanguard Capital Management held 278,190 shares of Greenwich LifeSciences worth $6.53M as of Q2 2026.
  • Vanguard Capital Management sold 20,076 Greenwich LifeSciences shares in Q2 2026, an estimated $488K.
  • Greenwich LifeSciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3020 holding.
  • Vanguard Capital Management first reported a position in Greenwich LifeSciences in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Greenwich LifeSciences position peaked at $7.16M in Q1 2026.
  • 58 funds tracked by Wall St. Rank held Greenwich LifeSciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.